Sustained IRE1 and ATF6 signaling is important for survival of melanoma cells undergoing ER stress

Cellular Signalling

Volumn 26, Issue 2, 2014, Pages 287-294

  Tay, Kwang Hong ^a   Luan, Qi ^a   Croft, Amanda ^a,b   Jiang, Chen Chen ^a   Jin, Lei ^a   Zhang, Xu Dong ^a   Tseng, Hsin Yi ^a  

^a UNIVERSITY OF NEWCASTLE   (Australia)

^b CALVARY MATER NEWCASTLE HOSPITAL   (Australia)

Author keywords

Endoplasmic reticulum stress; ERK; Melanoma; UPR

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 6; MITOGEN ACTIVATED PROTEIN KINASE; PERK PROTEIN; PROTEIN IRE1; PROTEIN IRE1ALPHA; PROTEIN KINASE; SHORT HAIRPIN RNA; THAPSIGARGIN; TUNICAMYCIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; ATF6 GENE; CANCER CELL CULTURE; CELL PROTECTION; CELL SURVIVAL; CONTROLLED STUDY; ENDOPLASMIC RETICULUM STRESS; ENZYME ACTIVATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; INTRACELLULAR SIGNALING; IRE1ALPHA GENE; MELANOMA; MELANOMA CELL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN FUNCTION; UNFOLDED PROTEIN RESPONSE;

ENDOPLASMIC RETICULUM STRESS; ERK; MELANOMA; UPR;

ACTIVATING TRANSCRIPTION FACTOR 6; CELL LINE, TUMOR; EIF-2 KINASE; ENDOPLASMIC RETICULUM STRESS; ENDORIBONUCLEASES; EUKARYOTIC INITIATION FACTOR-2; HEK293 CELLS; HUMANS; MELANOMA; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; PROTEIN-SERINE-THREONINE KINASES; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; THAPSIGARGIN; TUNICAMYCIN; UNFOLDED PROTEIN RESPONSE;

EID: 84889602190     PISSN: 08986568     EISSN: 18733913     Source Type: Journal    
DOI: 10.1016/j.cellsig.2013.11.008     Document Type: Article

References (40)

1. Harding H.P., et al. Annu. Rev. Cell Dev. Biol. 2002, 18:575-599.
2. Schroder M., Kaufman R.J. Annu. Rev. Biochem. 2005, 74:739-789.
3. Zhang K., Kaufman R.J. J. Biol. Chem. 2004, 279(25):25935-25938.
4. Boyce M., Yuan J. Cell Death Differ. 2006, 13(3):363-373.
5. Ferri K.F., Kroemer G. Nat. Cell Biol. 2001, 3(11):E255-E263.
6. Hitomi J., et al. J. Cell Biol. 2004, 165(3):347-356.
7. Li J., Lee B., Lee A.S. J. Biol. Chem. 2006, 281(11):7260-7270.
8. McCullough K.D., et al. Mol. Cell. Biol. 2001, 21(4):1249-1259.
9. Lin J.H., et al. Science 2007, 318(5852):944-949.
10. Rutkowski D.T., et al. PLoS Biol. 2006, 4(11):e374.
11. Lin J.H., et al. PLoS One 2009, 4(1):e4170.
12. Puthalakath H., et al. Cell 2007, 129(7):1337-1349.
13. Tay K.H., et al. Cell Death Dis. 2012, 3:e337.
14. Hersey P., Zhang X.D. Pigment Cell Melanoma Res. 2008, 21(3):358-367.
15. Jiang C.C., et al. Cancer Res. 2008, 68(16):6708-6717.
16. Jiang C.C., et al. Carcinogenesis 2009, 30(2):197-204.
17. Jiang C.C., et al. Cell Death Dis. 2010, 1(9):e69.
18. Ye Y., et al. Nat. Commun. 2013, 4:1508.
19. Jiang C.C., et al. Clin. Cancer Res. 2011, 17(4):721-730.
20. Yang F., et al. Cell Death Differ. 2010, 17(8):1354-1367.
21. Baumeister P., et al. Mol. Cell. Biol. 2005, 25(11):4529-4540.
22. Jiang C.C., et al. Cancer Res. 2007, 67(20):9750-9761.
23. Lee A.S. Methods 2005, 35(4):373-381.
24. Dong L., et al. Oncogene 2011, 30(34):3716-3726.
25. Croft A., et al. J. Invest. Dermatol. 2013, (in press). 10.1038/jid.2013.325.
26. Volkmann K., et al. J. Biol. Chem. 2011, 286(14):12743-12755.
27. Davies H., et al. Nature 2002, 417(6892):949-954.
28. Platz A., et al. Mol. Oncol. 2008, 1(4):395-405.
29. Jiang C.C., et al. Neoplasia 2009, 11(9):945-955.
30. Jiang C.C., et al. Neoplasia 2009, 11(5):436-447.
31. Lee A.S. Cancer Res. 2007, 67(8):3496-3499.
32. Ma Y., Hendershot L.M. Nat. Rev. Cancer 2004, 4(12):966-977.
33. Wang G., Yang Z.Q., Zhang K. Am. J. Transl. Res. 2010, 2(1):65-74.
34. Xu C., Bailly-Maitre B., Reed J.C. J. Clin. Invest. 2005, 115(10):2656-2664.
35. Chen L.H., et al. Cancer Res. 2008, 68(3):834-842.
36. Hersey P., Zhuang L., Zhang X.D. Int. Rev. Cytol. 2006, 251:131-158.
37. Zhuang L., et al. Histopathology 2009, 54(4):462-470.
38. Tabas I., Ron D. Nat. Cell Biol. 2011, 13(3):184-190.
39. Mhaidat N.M., et al. Anticancer Drugs 2009, 20(7):601-606.
40. Zhang L.J., et al. Cancer Lett. 2009, 274(1):40-46.